PE20010917A1 - Forma cristalina de eplerenona que muestra un aumento en la velocidad de disolucion - Google Patents
Forma cristalina de eplerenona que muestra un aumento en la velocidad de disolucionInfo
- Publication number
- PE20010917A1 PE20010917A1 PE2000001300A PE0013002000A PE20010917A1 PE 20010917 A1 PE20010917 A1 PE 20010917A1 PE 2000001300 A PE2000001300 A PE 2000001300A PE 0013002000 A PE0013002000 A PE 0013002000A PE 20010917 A1 PE20010917 A1 PE 20010917A1
- Authority
- PE
- Peru
- Prior art keywords
- eplerenone
- refers
- crystal
- dicarboxylate
- crystaline
- Prior art date
Links
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 title abstract 9
- 229960001208 eplerenone Drugs 0.000 title abstract 8
- 238000004090 dissolution Methods 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 abstract 3
- 238000002425 crystallisation Methods 0.000 abstract 2
- 230000008025 crystallization Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- XNSDIIWFWKXZBT-PGBIDFRPSA-N 3-[(1R,2S,10R,11S,14S,15S)-14-hydroxy-9-methoxycarbonyl-2,15-dimethyl-5-oxo-18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-en-14-yl]propanoic acid Chemical compound C1[C@]2(C)[C@](CCC(O)=O)(O)CC[C@H]2[C@@H]2C(C(=O)OC)CC3=CC(=O)CC[C@]3(C)[C@@]32OC31 XNSDIIWFWKXZBT-PGBIDFRPSA-N 0.000 abstract 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16963999P | 1999-12-08 | 1999-12-08 | |
| US16968299P | 1999-12-08 | 1999-12-08 | |
| US16960899P | 1999-12-08 | 1999-12-08 | |
| US16955699P | 1999-12-08 | 1999-12-08 | |
| US16969099P | 1999-12-08 | 1999-12-08 | |
| US16980799P | 1999-12-08 | 1999-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010917A1 true PE20010917A1 (es) | 2001-09-10 |
Family
ID=27558585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001300A PE20010917A1 (es) | 1999-12-08 | 2000-12-06 | Forma cristalina de eplerenona que muestra un aumento en la velocidad de disolucion |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1177204A2 (enExample) |
| JP (1) | JP2003516414A (enExample) |
| KR (1) | KR100607923B1 (enExample) |
| CN (2) | CN1152886C (enExample) |
| AU (1) | AU784946B2 (enExample) |
| BR (1) | BR0008057A (enExample) |
| CA (1) | CA2362669A1 (enExample) |
| CO (1) | CO5280211A1 (enExample) |
| EA (1) | EA007934B1 (enExample) |
| HU (1) | HUP0203032A3 (enExample) |
| IL (3) | IL144764A0 (enExample) |
| MX (1) | MXPA01008056A (enExample) |
| MY (1) | MY131878A (enExample) |
| NO (1) | NO20013856L (enExample) |
| NZ (2) | NZ530028A (enExample) |
| PE (1) | PE20010917A1 (enExample) |
| WO (1) | WO2001042272A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1487540A2 (en) * | 2002-03-20 | 2004-12-22 | Pharmacia Corporation | Storage stable eplerenone formulation |
| US7235655B2 (en) | 2002-03-22 | 2007-06-26 | Pharmacia & Upjohn Company | Processes to prepare eplerenone |
| CA2582496A1 (en) | 2007-03-20 | 2008-09-20 | Apotex Pharmachem Inc. | Improved process for the preparation and purification of eplerenone |
| EP2568986B1 (en) | 2010-05-10 | 2016-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| EP2582365B1 (en) | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
| US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| CN108059648A (zh) * | 2017-12-30 | 2018-05-22 | 合肥久诺医药科技有限公司 | 一种依普利酮溶剂合物及其制备方法 |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
| WO2023204729A1 (ru) * | 2022-04-19 | 2023-10-26 | Общество с ограниченной ответственностью "Гелеспон" | Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции |
| CN120754115A (zh) * | 2025-05-23 | 2025-10-10 | 远大医药（中国）有限公司 | 一种含依普利酮组合物及其药物制剂、制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559332A (en) * | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| NZ336004A (en) * | 1996-12-11 | 2001-04-27 | G | Process for preparation of 3-keto-7-alpha-alkoxycarbonyl substituted delta-4,5-steroid by reacting 4,5-dihydro-5,7-lactone steroid substrate in the presence of a base |
| JP2002538172A (ja) * | 1999-03-05 | 2002-11-12 | ジー．ディー．サール エルエルシー | 循環器疾患治療のためのアンギオテンシン変換酵素阻害薬およびエポキシ−ステロイドアルドステロン拮抗薬の組合せ療法 |
-
2000
- 2000-12-04 CN CNB008057788A patent/CN1152886C/zh not_active Expired - Fee Related
- 2000-12-04 HU HU0203032A patent/HUP0203032A3/hu unknown
- 2000-12-04 MX MXPA01008056A patent/MXPA01008056A/es not_active Application Discontinuation
- 2000-12-04 NZ NZ530028A patent/NZ530028A/en not_active IP Right Cessation
- 2000-12-04 EP EP00983781A patent/EP1177204A2/en not_active Withdrawn
- 2000-12-04 KR KR1020017010043A patent/KR100607923B1/ko not_active Expired - Fee Related
- 2000-12-04 WO PCT/US2000/032416 patent/WO2001042272A2/en not_active Ceased
- 2000-12-04 JP JP2001543569A patent/JP2003516414A/ja not_active Withdrawn
- 2000-12-04 EA EA200100871A patent/EA007934B1/ru not_active IP Right Cessation
- 2000-12-04 NZ NZ513961A patent/NZ513961A/xx not_active IP Right Cessation
- 2000-12-04 IL IL14476400A patent/IL144764A0/xx active IP Right Grant
- 2000-12-04 AU AU20492/01A patent/AU784946B2/en not_active Ceased
- 2000-12-04 CA CA002362669A patent/CA2362669A1/en not_active Abandoned
- 2000-12-04 CN CNA2004100368081A patent/CN1557833A/zh active Pending
- 2000-12-04 BR BR0008057-8A patent/BR0008057A/pt not_active IP Right Cessation
- 2000-12-06 MY MYPI20005734A patent/MY131878A/en unknown
- 2000-12-06 PE PE2000001300A patent/PE20010917A1/es not_active Application Discontinuation
- 2000-12-11 CO CO00094075A patent/CO5280211A1/es not_active Application Discontinuation
-
2001
- 2001-08-06 IL IL144764A patent/IL144764A/en not_active IP Right Cessation
- 2001-08-08 NO NO20013856A patent/NO20013856L/no not_active Application Discontinuation
-
2006
- 2006-06-22 IL IL176511A patent/IL176511A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0203032A3 (en) | 2003-04-28 |
| BR0008057A (pt) | 2002-04-23 |
| CN1377365A (zh) | 2002-10-30 |
| WO2001042272A9 (en) | 2002-12-12 |
| CA2362669A1 (en) | 2001-06-14 |
| WO2001042272A2 (en) | 2001-06-14 |
| IL144764A (en) | 2007-08-19 |
| MXPA01008056A (es) | 2003-07-21 |
| HUP0203032A2 (hu) | 2002-12-28 |
| NO20013856D0 (no) | 2001-08-08 |
| KR100607923B1 (ko) | 2006-08-04 |
| EA007934B1 (ru) | 2007-02-27 |
| KR20010112261A (ko) | 2001-12-20 |
| HK1050536A1 (en) | 2003-06-27 |
| NZ513961A (en) | 2004-02-27 |
| NZ530028A (en) | 2005-08-26 |
| WO2001042272A3 (en) | 2001-11-29 |
| IL144764A0 (en) | 2002-06-30 |
| AU784946B2 (en) | 2006-08-03 |
| CN1152886C (zh) | 2004-06-09 |
| EA200100871A1 (ru) | 2002-04-25 |
| CN1557833A (zh) | 2004-12-29 |
| CO5280211A1 (es) | 2003-05-30 |
| JP2003516414A (ja) | 2003-05-13 |
| NO20013856L (no) | 2001-10-08 |
| EP1177204A2 (en) | 2002-02-06 |
| MY131878A (en) | 2007-09-28 |
| AU2049201A (en) | 2001-06-18 |
| IL176511A (en) | 2007-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018107A1 (es) | Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo | |
| ES2104797T3 (es) | Composiciones farmaceuticas con actividad antagonista de angiotensina-ii. | |
| DE60104053D1 (de) | System zur photovoltaischen Energieerzeugung im Weltraum, energieerzeugender Satellit und kontrollierender Satellit | |
| CO5670355A2 (es) | Forma cristalina de sal de calcio de acido bis [(e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3r,5s)-3,5-dihidroxihept-6-enoico | |
| PE20070492A1 (es) | Forma cristalina delta del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen | |
| PE20010918A1 (es) | Forma cristalina de eplerenona | |
| CR8800A (es) | Regimenes y equipos anticonceptivos de antagonistas del receptor de progesterona | |
| PE20010911A1 (es) | Forma en estado solido de celecoxib que tiene una biodisponibilidad mejorada | |
| JP2012131697A (ja) | 二酸化炭素の固定化方法 | |
| GB201012302D0 (en) | Compositions suitable for cleaning medical devices | |
| CO5280211A1 (es) | Forma de cristal de eplerenona que exhibe mejorada rata de disolucion | |
| JP2008176935A (ja) | 鋼管ポール | |
| EA200701649A1 (ru) | Процесс выделения энергии и устройство для его осуществления | |
| Lotti et al. | Evidence that cholecystokinin octapeptide (CCK-8) acts as a potent, full agonist on gastrin receptors for acid secretion in the isolated mouse stomach: lack of antagonism by the specific CCK antagonist asperlicin | |
| CN204199780U (zh) | 一种用于灾后就地救援的生命方舟 | |
| CN104314326A (zh) | 一种用于灾后就地救援的生命方舟 | |
| CN105059326A (zh) | 一种太阳能列车到站监控系统 | |
| Carveni et al. | La Salsa e la Gurna di Fondachello: evoluzione di un vulcano di fango e di uno stagno costiero all’estrema periferia nord-orientale dell’edificio vulcanico etneo (Sicilia) | |
| Skok et al. | Pole Slip Protection on 400 kV Transsmision Line | |
| Bjegović et al. | Construction and Demolition Waste Usage Possibilities | |
| PA8852601A1 (es) | Antagonistas del receptor de angiotensina ii | |
| UA26948C2 (uk) | Спосіб одержаhhя моhокристалів кремhію при порушеhhі моhокристалічhого росту | |
| CN204947968U (zh) | 一种晶硅电池组件支架 | |
| Vujcic et al. | Hydrogen as Energy Carrier for Eco-Resorts on Dalmatian Islands | |
| CN203080505U (zh) | 斜嵌式拦沙网拦沙坝及其施工结构 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |